Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma.

Cancer Med · 2023 · PMC10709722 · PMID 37921243

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Looking at SR and HR patients, the 3‐year PFS was 59% versus 71% and 42% versus 66% for MRD+ and MRD−, respectively, but these differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.